DalsnaFinance Account

Illumina $ILMN

Healthcare · NYSE/NASDAQ

S&P 500 Russell 1000 California

Create a scorecard

$267.93

+5.27 (+2.01%)

As of Oct 21, 2026, 4:39 AM EDT · cached

Price history

Loading chart…

Key facts

52-week range (closes): $91.00 – $293.69 Lowest close Oct 14, 2025, highest Oct 5, 2026; 251 daily closes to Oct 13, 2026 from Dalsna Finance's price archive
Next earnings: Oct 29, 2026, after the close · EPS forecast $1.38 Nasdaq earnings calendar, as of Oct 21, 2026
Fiscal year ends: December Fiscal 2025 ended Dec 28, 2025, from SEC filings
In the S&P 500 since: Sep 21, 2026, replacing Molson Coors (TAP), The Trade Desk (TTD) and Builders FirstSource (BLDR) · Market capitalization changes. · All S&P 500 changes

Illumina (ILMN) is trading up at $267.93 (+2.01%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Healthcare sector.

Illumina revenue & net income history (FY2016–FY2025)

RevenueNet incomeNet margin (right axis, %)

Illumina annual financial statements
	FY2016Jan 2017	FY2017Dec 2017	FY2018Dec 2018	FY2019Dec 2019	FY2020Jan 2021	FY2021Jan 2022	FY2022Jan 2023	FY2023Dec 2023	FY2024Dec 2024	FY2025Dec 2025
Income statement
Revenue	$2.40B	$2.75B	$3.33B	$3.54B	$3.24B	$4.53B	$4.58B	$4.50B	$4.37B	$4.34B
Growth (year over year)	+8.0%	+14.8%	+21.1%	+6.3%	−8.6%	+39.7%	+1.3%	−1.7%	−2.9%	−0.7%
Gross profit	$1.67B	$1.83B	$2.30B	$2.47B	$2.20B	$3.15B	$2.97B	$2.74B	$2.86B	$2.87B
Gross margin	69.5%	66.4%	69.0%	69.6%	68.0%	69.7%	64.8%	60.9%	65.4%	66.1%
Operating income	$587.0M	$606.0M	$883.0M	$985.0M	$580.0M	−$123.0M	−$4.18B	−$1.07B	−$833.0M	$807.0M
Operating margin	24.5%	22.0%	26.5%	27.8%	17.9%	−2.7%	−91.2%	−23.7%	−19.1%	18.6%
Net income	$463.0M	$726.0M	$826.0M	$1.00B	$656.0M	$762.0M	−$4.40B	−$1.16B	−$1.22B	$850.0M
Net margin	19.3%	26.4%	24.8%	28.3%	20.3%	16.8%	−96.1%	−25.8%	−28.0%	19.6%
EPS (diluted)	$3.07	$4.92	$5.56	$6.74	$4.45	$5.04	−$28.00	−$7.34	−$7.69	$5.45
Balance sheet
Cash and equivalents	$735.0M	$1.23B	$1.14B	$2.04B	$1.81B	$1.23B	$2.01B	$1.05B	$1.13B	$1.42B
Total assets	$4.28B	$5.26B	$6.96B	$7.32B	$7.58B	$15.2B	$12.3B	$10.1B	$6.30B	$6.64B
Total liabilities	$2.01B	$2.51B	$3.11B	$2.70B	$2.89B	$4.48B	$5.65B	$4.37B	$3.93B	$3.92B
Long-term debt	$1.06B	$1.18B	$890.0M	$1.14B	$673.0M	—	—	—	—	—
Shareholders' equity	$2.20B	$2.75B	$3.76B	$4.61B	$4.69B	$10.7B	$6.60B	$5.75B	$2.37B	$2.72B
Cash flow
Operating cash flow	$779.0M	$875.0M	$1.14B	$1.05B	$1.08B	$545.0M	$392.0M	$478.0M	$837.0M	$1.08B
Capital expenditure	$260.0M	$310.0M	$296.0M	$209.0M	$189.0M	$208.0M	$286.0M	$195.0M	$128.0M	$148.0M
Free cash flow	$519.0M	$565.0M	$846.0M	$842.0M	$891.0M	$337.0M	$106.0M	$283.0M	$709.0M	$931.0M
Share buybacks	$249.0M	$251.0M	$201.0M	$324.0M	$736.0M	$0	$0	$0	$116.0M	$742.0M

RevenueNet incomeNet margin (right axis, %)

Illumina quarterly financial statements
	Q3 FY24Sep 2024	Q4 FY24^†Dec 2024	Q1 FY25Mar 2025	Q2 FY25Jun 2025	Q3 FY25Sep 2025	Q4 FY25^†Dec 2025	Q1 FY26Mar 2026	Q2 FY26Jun 2026
Income statement
Revenue	$1.08B	$1.10B	$1.04B	$1.06B	$1.08B	$1.16B	$1.09B	$1.16B
Growth (year over year)	−3.5%	−1.6%	−3.3%	−4.8%	+0.4%	+5.0%	+4.8%	+9.4%
Gross profit	$745.0M	$728.0M	$683.0M	$695.0M	$733.0M	$759.0M	$721.0M	$770.0M
Gross margin	69.0%	65.9%	65.6%	65.6%	67.6%	65.5%	66.1%	66.4%
Operating income	$741.0M	$174.0M	$164.0M	$214.0M	$227.0M	$202.0M	$209.0M	$245.0M
Operating margin	68.6%	15.8%	15.8%	20.2%	20.9%	17.4%	19.2%	21.1%
Net income	$705.0M	$186.0M	$131.0M	$235.0M	$150.0M	$334.0M	$134.0M	$207.0M
Net margin	65.3%	16.8%	12.6%	22.2%	13.8%	28.8%	12.3%	17.9%
EPS (diluted)	$4.42	$1.16	$0.82	$1.49	$0.98	$2.16	$0.87	$1.35
Balance sheet
Cash and equivalents	$869.0M	$1.13B	$1.11B	$934.0M	$1.05B	$1.42B	$1.09B	$1.04B
Total assets	$6.01B	$6.30B	$6.18B	$6.09B	$6.18B	$6.64B	$6.56B	$6.65B
Total liabilities	$3.89B	$3.93B	$3.81B	$3.83B	$3.80B	$3.92B	$3.88B	$3.81B
Shareholders' equity	$2.13B	$2.37B	$2.37B	$2.26B	$2.38B	$2.72B	$2.68B	$2.84B
Cash flow
Operating cash flow	$316.0M	$364.0M	$240.0M	$234.0M	$284.0M	$321.0M	$289.0M	$201.0M
Capital expenditure	$32.0M	$29.0M	$32.0M	$30.0M	$31.0M	$55.0M	$38.0M	$40.0M
Free cash flow	$284.0M	$335.0M	$208.0M	$204.0M	$253.0M	$266.0M	$251.0M	$161.0M
Share buybacks	$99.0M	$17.0M	$200.0M	$370.0M	$130.0M	$42.0M	$242.0M	$128.0M

From Illumina's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →

Illumina vs the Health Care sector and the S&P 500

Illumina's latest reported figures next to the median of the other 59 S&P 500 Health Care companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.

Illumina compared with the median Health Care company and the median S&P 500 company
Measure	Illumina	Health Care (59 other S&P 500 companies)	S&P 500 (502 other companies)
Revenue growth, latest fiscal year	−0.7%	+7.2%	+7.0%
Net margin, latest fiscal year	19.6%	12.9%	12.9%
Share price change, 1 year	+170.7%	+20.7%	+6.6%

Illumina: fiscal year ended December 2025, from its 10-K and 10-Q filings with the SEC. Medians computed October 21, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, Illumina included, are the last regular-session prices of October 20, 2026; the 1-year change compares that price with each company's last close on or before October 21, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 59/496, net margin 59/496, 1-year price change 59/488; the reasons below can overlap. 14 are left out of the price figure because our archive holds no comparable close for them. The S&P 500 price figure is the middle company's change, not the index's return.

About Illumina

Illumina, Inc. is an American biotechnology company, headquartered in San Diego, California. Incorporated on April 1, 1998, Illumina develops, manufactures, and markets integrated systems for the analysis of genetic variation and biological function. The company provides a line of products and services that serves the sequencing, genotyping and gene expression, and proteomics markets, and serves more than 155 countries.

Source: Wikipedia — Illumina, Inc.